10-Q: DiaMedica Therapeutics Faces Trial Delays, Rising Costs

DiaMedica Therapeutics Inc. reported increased operating expenses and ongoing challenges with clinical trial site activations and enrollment in its ReMEDy2 trial for acute ischemic stroke.

Summary

• DiaMedica Therapeutics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a net loss of $10.1 million for the quarter and $20.2 million for the six months ended June 30, 2026.
• The company experienced increased research and development (R&D) expenses, rising to $8.2 million for the quarter and $16.1 million for the six months, primarily due to clinical team expansion, the ReMEDy2 trial, and reproductive toxicity testing.
• General and administrative (G&A) expenses were $2.3 million for the quarter and $4.8 million for the six months, with increases attributed to share-based compensation and personnel costs.
• As of June 30, 2026, the company had $5.1 million in cash and cash equivalents and $43.5 million in combined cash, cash equivalents, and marketable securities.
• The company continues to face challenges with site activations and enrollment in its ReMEDy2 trial for acute ischemic stroke, attributing these to hospital staffing shortages and other factors.
• Progress is being made in the preeclampsia (PE) and fetal growth restriction (FGR) programs, with interim results from Part 1a of the investigator-sponsored trial showing DM199 to be safe and well-tolerated with pharmacodynamic activity.
• The company expects its current cash resources to be sufficient for at least the next 12 months but anticipates needing substantial additional capital for ongoing development and regulatory activities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the continued operational losses, significant cash burn, and the ongoing challenges in clinical trial enrollment, despite the company's progress in its development programs.

Positives

• Interim results from Part 1a of the PE/FGR investigator-sponsored trial demonstrated DM199 is safe, well-tolerated, and shows clinically relevant pharmacodynamic activity, including sustained reductions in maternal blood pressure.
• No evidence of placental transfer of DM199 was observed in the PE/FGR trial.
• The company received approval from Health Canada to initiate a global Phase 2 trial for early-onset PE.
• Enrollment in the ReMEDy2 trial for AIS has reached 85% of the participants required for the interim analysis.
• The company has expanded its internal clinical team and brought certain trial activities in-house to mitigate enrollment challenges.

Negatives

• Net loss for the three months ended June 30, 2026, was $10.1 million, and $20.2 million for the six months ended June 30, 2026.
• Operating expenses increased, with R&D expenses rising by approximately 40% for the quarter and 40% for the six months compared to the prior year periods.
• The company continues to experience slower than expected site activations and enrollment in the ReMEDy2 trial for AIS.
• As of June 30, 2026, the company had an accumulated deficit of $192.9 million.
• Cash and cash equivalents decreased to $5.1 million from $15.6 million at the end of 2025.
• The company expects to continue incurring substantial operating losses and requires significant additional capital for future development.

Risks

• Slower than expected site activations and enrollment in the ReMEDy2 trial for AIS due to hospital staffing shortages, inclusion/exclusion criteria, logistical concerns, prior hypotension events, and competition for trial subjects.
• Uncertainties related to regulatory applications and approval timelines, especially given potential changes in FDA funding and staffing.
• The possibility of future adverse events or unfavorable trial results that could impact other current or future trials.
• The adaptive design of the ReMEDy2 trial means the final sample size could range from 300 to 728 patients, impacting timelines and costs.
• The FDA requested additional non-clinical reproductive toxicity data for DM199 for PE, and the company is initiating a pharmacokinetic study in rats to address this.
• Failure to resolve issues impacting ReMEDy2 trial site activations and enrollment may result in further delays and forecasting difficulties.
• The company has not completed development of any product candidate and does not generate revenue from commercial sales, with DM199 not expected to be commercially available for at least three to four years, if at all.
• The company's future success is dependent on demonstrating clinical progress, obtaining regulatory approvals, and securing additional financing.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for at least the next few years as it advances its DM199 clinical development program. Quarterly expenses are anticipated to increase moderately due to clinical trial advancements, global expansion, and team growth. While current cash resources are expected to fund operations for at least the next 12 months, substantial additional capital will be required for further R&D, clinical studies, regulatory activities, and potential commercialization.

Management Comments

• "We believe that DM199 is uniquely suited to treat PE since its inherent molecular size, approximately 26 kilodaltons (KD) is typically too large to cross the placental barrier, as was demonstrated in the interim results noted below, and therefore may reduce blood pressure and enhance microcirculatory perfusion to the maternal organs and placenta without entering fetal circulation, a potentially significant safety advantage."
• "In the case of AIS, DM199 is intended to enhance collateral blood flow and boost neuronal survival in the ischemic penumbra by inhibiting neuronal cell death (apoptosis) and promoting neuronal remodeling and neoangiogenesis, and accordingly, offer a potential treatment option for AIS patients who otherwise have no therapeutic options."
• "We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events; use of artificial intelligence and telemedicine... and competition for research staff and trial subjects..."
• "We expect our current cash resources will be sufficient to allow us to fund our planned operations for at least the next 12 months from the date of issuance of the condensed consolidated financial statements included in this report."

Industry Context

StockSavvy.ai notes that DiaMedica Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, where clinical trial success and regulatory approvals are critical determinants of value. The company's focus on preeclampsia, fetal growth restriction, and acute ischemic stroke addresses significant unmet medical needs. However, the challenges in trial enrollment and the lengthy development timelines are common hurdles faced by companies in this space, underscoring the importance of robust financing and effective clinical operations management.

Comparison to Industry Standards

• The company's R&D expenses as a percentage of total operating expenses are high, which is typical for clinical-stage biopharmaceutical companies investing heavily in drug development.
• The net loss and accumulated deficit are consistent with industry peers in the early to mid-stages of drug development, where significant investment precedes revenue generation.
• The challenges in clinical trial enrollment (site activation and patient recruitment) are not unique to DiaMedica and are frequently cited by other biopharmaceutical companies as significant operational risks, often exacerbated by external factors like healthcare system staffing shortages.
• The need for substantial additional capital to fund ongoing operations and development is a standard characteristic of the biopharmaceutical industry, where drug development is a long and expensive process.

Legal Proceedings

• The company is not currently engaged in or aware of any threatened legal actions.

Stakeholder Impact

• Shareholders: Continued operational losses and the need for future capital raises may lead to dilution. Trial delays and clinical setbacks could negatively impact share price.
• Employees: Increased R&D expenses include personnel costs, suggesting continued investment in the team, but future funding uncertainties could pose risks.
• Creditors: As the company primarily relies on equity financing, direct impact on creditors is minimal, but overall financial health impacts long-term viability.
• Suppliers: Increased R&D and clinical trial activities may lead to higher demand for services from contract research organizations and other suppliers.

Next Steps

• Present detailed Part 1a results from the PE/FGR trial at an upcoming medical conference and submit for publication.
• Initiate Part 1b and Part 2 studies for the PE investigator-sponsored trial in September or October 2026.
• Complete the rat pharmacokinetic (PK) study in October 2026 to support the PE program's IND application.
• Submit requested information to the FDA regarding the PE program's non-clinical reproductive toxicity data.
• Continue to monitor and implement actions to enhance site activations and enrollment in the ReMEDy2 trial.
• Complete the interim analysis for the ReMEDy2 trial in the first quarter of 2027.

Key Dates

Recommendation

The company is in a high-risk, high-reward phase of drug development. While progress is being made with DM199 in PE/FGR and the ReMEDy2 trial is advancing, significant challenges remain with trial enrollment, regulatory hurdles, and the substantial capital required for future development. The current financial position and ongoing losses warrant a cautious approach. Investors should monitor clinical trial progress, regulatory feedback, and the company's ability to secure necessary funding. A 'hold' recommendation reflects the balance between potential upside from successful drug development and the significant risks involved.

Keywords

DiaMedica Therapeutics, DM199, preeclampsia, fetal growth restriction, acute ischemic stroke, clinical trials, biopharmaceutical, FDA